Like two ships passing in the night, Ocular Therapeutix Inc.'s request to extend the review period for its new drug application (NDA) for a post-surgical ocular pain product was followed roughly 24 hours later by a complete response letter to the NDA for Dextenza (dexamethasone insert).
Ocular's July 10 filing to the US FDA intended to close out the responses to the agency's Form 483 letter...







